Wielkopolskie Centrum Onkologii Im. Marii Sklodowskiej-Curie

The clinical research at Wielkopolskie Centrum Onkologii Im. Marii Sklodowskiej-Curie is centered on cancer care, with a strong focus on advanced and recurrent solid tumors. Studies in this area explore new treatment options and compare them with current standards to improve survival, disease control, and long-term outcomes.

• Breast, ovarian, endometrial, gastric, and colorectal cancers
• Head and neck, prostate, melanoma, cervical, and liver cancers
• Testing new immunotherapy and targeted therapy approaches

Much of the work aims to refine how systemic cancer treatments are used in patients with difficult-to-treat or high-risk disease, while also assessing whether newer combinations can offer better control than established therapies.

This site is actively involved in studies for breast cancer and ovarian cancer, including hormone receptor-positive disease, HER2-positive and HER2-low tumors, and platinum-sensitive or platinum-resistant ovarian cancer. The trials are designed to evaluate newer treatment strategies and improve outcomes for patients with recurrent, metastatic, or high-risk disease.

• Metastatic breast cancer and early breast cancer with high recurrence risk
• Ovarian, fallopian tube, and primary peritoneal cancers
• Evaluating targeted therapies, antibody-based treatments, and immunotherapy combinations

These studies focus on whether newer approaches can better delay progression and extend survival compared with standard care, especially in patients whose disease has returned or spread.

Research in gynecologic cancers includes endometrial cancer, cervical cancer, and advanced ovarian-related malignancies. The clinical trials are aimed at improving treatment effectiveness for patients with recurrent, metastatic, or treatment-resistant disease.

• Endometrial carcinoma, including pMMR and recurrent disease
• Locally advanced cervical cancer
• Ovarian, fallopian tube, and primary peritoneal cancers

At this oncology center, investigators are studying whether modern immunotherapy and targeted agents can improve disease control and reduce the risk of recurrence in women facing aggressive gynecologic cancers.

The site also contributes to research in digestive system cancers, especially colorectal cancer, gastric cancer, gastroesophageal junction cancer, and esophageal cancer. These trials are focused on patients with advanced, unresectable, or metastatic disease.

• Colorectal cancer with KRAS mutations and metastatic spread
• Advanced gastric and gastroesophageal junction cancer
• Esophageal squamous cell carcinoma

Research here is evaluating whether new targeted therapies and immunotherapy combinations can improve progression control and overall survival compared with standard treatment options.

Another important research stream at the site includes head and neck cancer, prostate cancer, and melanoma. These studies address both newly treated and recurrent or metastatic disease, with an emphasis on better disease control after surgery or during advanced illness.

• Recurrent or metastatic head and neck squamous cell carcinoma
• Castration-resistant prostate cancer
• High-risk stage III melanoma after complete resection

The purpose of these trials is to test whether newer immunotherapy and targeted treatment strategies can help prevent recurrence, slow progression, and improve survival in challenging cancers.